Immunotherapy in non-small cell lung cancer: steps towards more effective combination therapies

Non-small cell lung carcinoma (NSCLC), one of the most common causes of cancer death worldwide (1), is also where some of the most progressive and innovating breakthroughs are being made in oncologic research.